US 10,889,651 B2
Anti-Ly6E antibodies and methods of use
Jyoti Asundi, Foster City, CA (US); Ron Firestein, Burlingame, CA (US); Paul Polakis, Mill Valley, CA (US); Chie Sakanaka, Tokyo (JP); Peter Chang, Greenbrae, CA (US); and Rayna Takaki Venook, Millbrae, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Jul. 31, 2018, as Appl. No. 16/50,936.
Application 16/050,936 is a division of application No. 15/018,710, filed on Feb. 8, 2016, granted, now 10,066,022.
Application 15/018,710 is a division of application No. 14/518,294, filed on Oct. 20, 2014, granted, now 9,290,578, issued on Mar. 22, 2016.
Claims priority of provisional application 61/893,553, filed on Oct. 21, 2013.
Prior Publication US 2019/0085089 A1, Mar. 21, 2019
Int. Cl. C07K 16/30 (2006.01); G01N 33/574 (2006.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/30 (2013.01) [A61K 47/6803 (2017.08); A61K 47/6851 (2017.08); A61K 51/1045 (2013.01); G01N 33/574 (2013.01); G01N 33/57415 (2013.01); G01N 33/57419 (2013.01); G01N 33/57423 (2013.01); G01N 33/57438 (2013.01); G01N 33/57446 (2013.01); G01N 33/57449 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); G01N 2333/705 (2013.01)] 20 Claims
 
1. An in vitro method of detecting human Ly6E in a biological sample comprising contacting the biological sample with an isolated antibody that binds to human Ly6E comprising the amino acid sequence of SEQ ID NO: 38, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:32, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:34, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:29, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:30, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:31, and detecting whether a complex is formed between the anti-Ly6E antibody and the human Ly6E in the biological sample, wherein the method comprises a control, and
wherein (i) the antibody is conjugated to a label and detecting the complex comprises detecting the label; or (ii) detecting the complex comprises detecting the antibody with a labeled secondary antibody.